Suppr超能文献

基于纳米荧光素酶的互补测定法检测 G 蛋白偶联受体- G 蛋白相互作用。

Nanoluciferase-Based Complementation Assay to Detect GPCR-G Protein Interaction.

机构信息

Laboratory of Molecular Pharmacology, GIGA-Molecular Biology of Diseases, University of Liège, Liège, Belgium.

Laboratory of Medicinal Chemistry, Centre for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium.

出版信息

Methods Mol Biol. 2021;2268:149-157. doi: 10.1007/978-1-0716-1221-7_10.

Abstract

G protein-coupled receptors (GPCR) are one of the principal class of membrane proteins and around 30% of the currently marketed drugs act on one of them. The efficacious detection of ligands with the desired pharmacological profile remains a challenge of paramount importance in the GPCR drug discovery and pharmacological research. Recent evidences demonstrate that GPCR ligands can stabilize distinct receptor conformation and trigger various signaling pathways with different efficacies and/or potencies. This phenomenon called functional selectivity or biased signaling may lead to improved drugs with fewer side effects. Most receptors are promiscuous and can couple to more than one G protein family. To enable the discovery of biased ligands able to selectively trigger one G protein pathway over another, simple and efficient screening procedures are needed. The traditional assays aiming at detecting G protein activation monitor the generation of second messengers ([Ca], cAMP, IP) or active G proteins (with GTP-g-S for instance). While these approaches have proven sensitive and robust, they are not suited for the detection of a single GPCR-G protein interaction. Here, we present in detail a method to assess directly the interaction between the receptor and the G protein. It permits the profiling of a receptor or a ligand toward G protein interactions and is compatible with high-throughput screening.

摘要

G 蛋白偶联受体(GPCR)是主要的膜蛋白之一,目前市场上约 30%的药物作用于其中一种。有效地检测具有所需药理学特征的配体仍然是 GPCR 药物发现和药理学研究中至关重要的挑战。最近的证据表明,GPCR 配体可以稳定不同的受体构象,并触发具有不同效力和/或效价的各种信号通路。这种现象称为功能选择性或偏向性信号传导,可能导致副作用更少的改进药物。大多数受体是混杂的,可与不止一种 G 蛋白家族偶联。为了能够发现能够选择性地触发一种 G 蛋白途径而不是另一种途径的偏向性配体,需要简单有效的筛选程序。旨在检测 G 蛋白激活的传统测定方法监测第二信使([Ca]、cAMP、IP)或活性 G 蛋白(例如用 GTP-g-S)的产生。虽然这些方法已经被证明是敏感和稳健的,但它们不适合检测单个 GPCR-G 蛋白相互作用。在这里,我们详细介绍了一种直接评估受体与 G 蛋白相互作用的方法。它允许对受体或配体进行 G 蛋白相互作用的分析,并与高通量筛选兼容。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验